

Date: March 2, 2019

To NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
---	--

Dear Sirs,

Sub: Aurobindo Completes the Acquisition of Marketed Portfolio from Spectrum Pharmaceuticals

We refer to our earlier letter dated January 17, 2019 informing about the entering into a definitive agreement to acquire seven marketed oncology injectable products, intellectual property and commercial infrastructure from Spectrum Pharmaceuticals Inc., (NASDAQ:SPPI), a US based global branded oncology company by Acrotech Biopharma L.L.C., a wholly owned subsidiary of Aurobindo Pharma USA Inc., USA, which in turn is a wholly owned subsidiary of the Company.

In this regard, we would like to inform you that the aforesaid acquisition has been completed on March 1, 2019.

This is for your information and record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED



B. Adi Reddy
Company Secretary

